Matt Hoffman

Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.

The FDA is set to complete its review of FT218 by June 17, 2023, and Avadel has indicated its expectation that the investigational treatment for excessive daytime sleepiness and cataplexy in adults with narcolepsy will be approved.

Stephen Krieger, MD, of the Icahn School of Medicine and Corinne Goldsmith Dickinson Center for MS at Mount Sinai, shared his perspectives on the trends in multiple sclerosis and the need to holistically treat patients to maximize brain reserve.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is World MS Day.

David Evans, MBA, shared his experience from this year’s event and spoke about the progress that’s been made in advocating for patients in the last several years at the AAN's Neurology on the Hill conference.

June Halper, MSN, APC-C, MSCN, FAAN, the chief executive officer of the Consortium of Multiple Sclerosis Centers, shared her perspective on what to expect from this year’s annual meeting, which takes place June 1-4, 2022, in National Harbor, Maryland.

The director of the MedStar Georgetown Headache Center shared her clinical understanding of new therapies for migraine and how the paradigm shift in care has altered the experience for both patients and physicians.

The new ASA/AHA guidance, updating the prior 2015 publication, provides several significant recommendations and changes, including those for the use of antiseizure medications in patients with ICH.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuropathic disorders.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Matthew B. Harms, MD. [LISTEN TIME: 28 minutes]

The blood test from Diadem SpA, which quantifies the AZ 284 peptide as readout of U-p53AZ, showed a significantly higher AUC in both time-independent and time-dependent prognostic analyses than gold standard testing.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

The cofounder and chief scientist at Big Health and professor of sleep medicine at the University of Oxford discussed the recent findings of a study of Sleepio in poststroke rehabilitation and the role that cognitive behavioral therapy could play in that care process.

John F. Crary, MD, PhD, and Jerry Fernandez, MD, offer insight into PreciseDx's AI Morphology Feature Array and how this technology can improve neuropathology and diagnosis for neurodegenerative diseases, such as Parkinson disease.

A Harris Poll conducted by Quest Diagnostics suggests that more than 65% of US physicians believe the Alzheimer disease field is on the cusp of a breakthrough, with more than 80% noting that earlier evaluation with blood testing may help improve therapeutic approaches.

The digital cognitive behavioral therapy improved sleep for almost half of the study cohort and showed additional signs of improvement for depression and anxiety among individuals in rehabilitation for stroke.

With a burst of activity in recent months, the pipeline of development for amyotrophic lateral sclerosis has proven to be a miniature likeness of the wider progress being made in the care and management of neuromuscular disorders.

The director of the pediatric epilepsy program at Boston Children’s Health Physicians shared his expertise with the challenges associated with diagnosing LGS, how the REST-LGS tool may help, and the need to collect more data.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jessica Ailani, MD. [LISTEN TIME: 35 minutes]

DSP-0187, an orexin-2 receptor agonist, adds to Jazz’s portfolio of sleep disorder therapies, expanding it into a new medicine class. The molecule will be referred to as JZP441 by Jazz.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The phase 2 study will feature a 24-week treatment period followed by an 80-week open-label treatment period with the small-molecule RIPK1 inhibitor. It seeks to enroll 260 patients with ALS.

Axsome expects to address the concerns in the letter and plans to resubmit AXS-07. The MoSEIC meloxicam-rizatriptan combination significantly reduced migraine symptoms and pain compared with placebo and both active agents in a pair of phase 3 trials.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Shurjal Baxi, MD, MPH, the senior vice president of Clinical and Scientific Solutions at Verana Health, shared her perspective on the AAN’s Axon Registry and how quality data collection can drive improvements in patient care and management.

Peter J. McAllister, MD, FAAN, medical director and chief medical officer, New England Center for Neurology and Headache, offered his insight into data from the phase 2 STEMTRA trial in TBI and the trends he’s observed in the field of regenerative medicine.

Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.

Patients who switched from a twice-nightly stable regimen of Xyrem or Xywav to once-nightly FT218 reported that they preferred the new dosing schedule, along with challenges in adherence to twice-nightly dosing.

Following an NCD that will allow for Medicare coverage of the therapy only in NIH- and FDA-approved studies and trials, Biogen has pulled its application to the European Medicines Agency for aducanumab treatment in Alzheimer disease.